Latest News for: science ltd

Edit

Initial Statement of Beneficial Ownership (Form 3) (Tiziana Life Sciences Ltd)

Public Technologies 19 Mar 2026
) FORM 3. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C ... OMB Number. 3235-0104 ... 0.5 ... 2 ... Tiziana Life Sciences Ltd [TLSA] ... C/O TIZIANA LIFESCIENCES LTD, 14-15 CONDUIT STREET 4 ... 5 ... 4) 2 ... C/O TIZIANA LIFESCIENCES LTD ... Tiziana Life Sciences Ltd.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Roivant Sciences Ltd)

Public Technologies 19 Mar 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... 0.5 ... 2 ... Roivant Sciences Ltd ... C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY 3 ... 6 ... C/O ROIVANT SCIENCES LTD ... Roivant Sciences Ltd.
Edit

Notice of Proposed Sale of Securities (Form 144) (Roivant Sciences Ltd)

Public Technologies 17 Mar 2026
). The text version of this document is not available ... Roivant Sciences Ltd.
Edit

Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer (Lobe Sciences Ltd)

Public Technologies 09 Mar 2026
). The text version of this document is not available ... Lobe Sciences Ltd.
Edit

Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences

ACCESSWIRE 05 Mar 2026
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd ... The Company announces that its Chief Executive Officer, Dr. Frederick D ... About Lobe Sciences Ltd. Lobe Sciences Ltd ... Dr. Frederick D ... Lobe Sciences Ltd ... Lobe Sciences Ltd ... ....
Edit

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna (Form 8-K) (Roivant Sciences Ltd)

Public Technologies 03 Mar 2026
) Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna ... ROIV) today announced that Genevant Sciences, a ... About Genevant Sciences ... Roivant Sciences Ltd.
Edit

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis (Form 8-K) (Roivant Sciences Ltd)

Public Technologies 03 Mar 2026
) Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis. • ... • ... •. If approved, brepocitinib would represent the first targeted therapy approved for dermatomyositis ... Roivant Sciences Ltd ... (noodl.
Edit

LNP Litigation Settlement with Moderna vF (Roivant Sciences Ltd)

Public Technologies 03 Mar 2026
). LNP Litigation. Settlement with Moderna. March 3, 2026. Settlement Validates the Seminal Work of Genevant/Arbutus Inventors. ... Years in the Making. Feb. 2022. Nov. 2022. Early. 2023. Early. 2024. 2025. Early. 2026 ... The U.S ... U.S. taxpayers) ... $950M ... Roivant Sciences Ltd.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Wave Life Sciences Ltd)

Public Technologies 28 Feb 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... 0.5 ... 2 ... Wave Life Sciences Ltd ... C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE ... C/O WAVE LIFE SCIENCES LTD., ... Wave Life Sciences Ltd.
Edit

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (Form 8-K) (Wave Life Sciences Ltd)

Public Technologies 26 Feb 2026
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update ... CAMBRIDGE, Mass., February 26, 2026 - Wave Life Sciences Ltd ... About Wave Life Sciences. Wave Life Sciences (Nasdaq ... Wave Life Sciences Ltd.
Edit

Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) (Wave Life Sciences Ltd)

Public Technologies 26 Feb 2026
). MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ... Overview ... We maintain strong and broad intellectual property, including for our novel chemistry modifications ... This focus enables us to ... 2025 ... Wave Life Sciences Ltd.
Edit

Listing of Securities Suven Life Sciences Ltd (BSE Ltd)

Public Technologies 25 Feb 2026
) NOTICES Notice No. 20260225-21 Notice Date 25 Feb 2026 ... Subject Listing of Securities Suven Life Sciences Ltd. Content. Trading members of the Exchange are hereby informed that the under mentioned new securities of Suven Life Sciences Ltd ... Dist ... BSE Ltd.
Edit

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA (Form 6-K) (Tiziana Life Sciences Ltd)

Public Technologies 25 Feb 2026
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab ... BOSTON, MA, February 25, 2026 - Tiziana Life Sciences, Ltd ... About Tiziana Life Sciences ... Tiziana Life Sciences Ltd.
Edit

SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development (SureNano Science Ltd)

Public Technologies 23 Feb 2026
). The text version of this document is not available ... SureNano Science Ltd.
Edit

Initial Registration Statement for Employee Benefit Plan (Form S-8) (Tiziana Life Sciences Ltd)

Public Technologies 20 Feb 2026
TIZIANA LIFE SCIENCES LTD ... 99.1 The Tiziana Life Sciences Ltd 2021 Equity Incentive Plan, incorporated by reference to Exhibit 10.3 of the Form 8-K, filed by Tiziana Life Sciences Ltd ... TIZIANA LIFE SCIENCES LTD ... Tiziana Life Sciences Ltd.

Article Search

tools
×
×
×
×